{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=26",
    "query": {
      "intervention": "Control label",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 3335,
    "total_pages": 334,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T11:20:01.323Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06658730",
      "title": "Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Vascular Disease",
        "Dissection",
        "Dissection Aortic Aneurysm",
        "Dissection of Aorta",
        "Aneurysm Thoracic",
        "Aneurysm Dissecting",
        "Transection Aorta",
        "Intramural Hematoma"
      ],
      "interventions": [
        {
          "name": "Endovascular",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "W.L.Gore & Associates",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1500,
      "start_date": "2025-06-19",
      "completion_date": "2038-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Stanford, California + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06658730"
    },
    {
      "nct_id": "NCT04566445",
      "title": "HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "GT005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gyroscope Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 255,
      "start_date": "2020-09-28",
      "completion_date": "2024-06-10",
      "has_results": true,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04566445"
    },
    {
      "nct_id": "NCT06361537",
      "title": "Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Hereditary Angio Edema"
      ],
      "interventions": [
        {
          "name": "OCTA-C1-INH",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2024-04-30",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 3,
      "location_summary": "Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06361537"
    },
    {
      "nct_id": "NCT07027345",
      "title": "A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa Simplex"
      ],
      "interventions": [
        {
          "name": "5% TolaSure Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "Topical Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMendics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-11",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07027345"
    },
    {
      "nct_id": "NCT07076862",
      "title": "Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "PASC Post Acute Sequelae of COVID-19"
      ],
      "interventions": [
        {
          "name": "A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)",
          "type": "DRUG"
        },
        {
          "name": "A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)",
          "type": "DRUG"
        },
        {
          "name": "B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)",
          "type": "DRUG"
        },
        {
          "name": "B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2025-12-04",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • San Francisco, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07076862"
    },
    {
      "nct_id": "NCT02153983",
      "title": "Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Metabolic Disease"
      ],
      "interventions": [
        {
          "name": "Colchicine 0.6Mg Cap",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules given",
          "type": "DRUG"
        },
        {
          "name": "Colchicine 0.6Mg Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 77,
      "start_date": "2014-05-31",
      "completion_date": "2018-08-15",
      "has_results": true,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02153983"
    },
    {
      "nct_id": "NCT04587622",
      "title": "Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Failure"
      ],
      "interventions": [
        {
          "name": "Icenticaftor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-10-30",
      "completion_date": "2022-09-15",
      "has_results": false,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04587622"
    },
    {
      "nct_id": "NCT02738151",
      "title": "Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin glargine, 300U/mL",
          "type": "DRUG"
        },
        {
          "name": "Insulin degludec, 100 U/mL",
          "type": "DRUG"
        },
        {
          "name": "Non-insulin anti-diabetic treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 929,
      "start_date": "2016-05-19",
      "completion_date": "2017-08-15",
      "has_results": true,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 74,
      "location_summary": "Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02738151"
    },
    {
      "nct_id": "NCT04780841",
      "title": "A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "RDX013",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardelyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 109,
      "start_date": "2021-01-11",
      "completion_date": "2022-03-03",
      "has_results": false,
      "last_update_posted_date": "2022-05-04",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 6,
      "location_summary": "Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04780841"
    },
    {
      "nct_id": "NCT02748694",
      "title": "Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "TAK-041",
          "type": "DRUG"
        },
        {
          "name": "TAK-041 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 114,
      "start_date": "2016-05-09",
      "completion_date": "2019-09-22",
      "has_results": true,
      "last_update_posted_date": "2021-03-19",
      "last_synced_at": "2026-10-22T11:20:01.323Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748694"
    }
  ]
}